The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.
The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.
Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/11805
– An overview of the global markets for cancer immunotherapies and oncolytic virology.
– Analyses of global market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
– Analyses of factors influencing market demand, such as clinical guidelines, demographic changes, and market saturation.
– Information covering the latest trends, market structure, market size, key drug segments, and trends in technology.
– Coverage of colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines, and other cancer treatment immunology products.
– Technological discussions, including the current state, newly issued patents, and pending applications.
– Profiles of leading companies in the industry.
Buy Now report with Analysis of COVID-19 @ https://www.trendsmarketresearch.com/checkout/11805/Single
Cancer is a disease with global implications. There are many different types of cancer, of which the most common types include lung, breast, colon and rectal, stomach, head and neck, prostate, cervical, melanoma, and ovarian cancer, as well as leukemia. Cancer is a genetic disease that is conventionally treated by surgery, radiation therapy, chemotherapy, hormonal therapy, and immunotherapy. Surgery is the mainstay treatment for all cancers. Usually surgery is complimented with radiation or chemotherapy to ensure the clearance of all residual cancer. Despite the advances in treatment, cancer has great plasticity; therefore, after a certain time the effects of treatment fade and cancer returns with acquired resistance. Combination therapy, using multiple modalities including surgery and pharmaceutical or radiation therapy, improves response to treatment.
Radiation and chemotherapy have many side effects. Biological treatment options provide less impactful treatment of cancer. Immunotherapy is a type of biological therapy and it incorporates elements of the immune system in cancer treatment. The immune system has various types of cells and proteins that detect and act upon signs of a disease or infection by harmful and foreign substances such as microbes, bacteria and viruses. The immune system differentiates the body’s own cells and tissues through an evolutionary bar-coding system. This system helps the immune system understand encountered foreign substances as “nonself.” Cancer cells are recognized as nonself as well. The immune system monitors the body for cancer and destroys when it detects a malignancy. Cancer cells can avoid being recognized by the immune system and develop resistance through numerous methods.
Since the early 1900s, the connection between cancer and the immune system has caught the attention of various scientists and medical practitioners. Although the early studies were bluntly done without current technological and scientific tools, they nonetheless shed insights leading to the development of the first monoclonal antibodies and to the use of biologically derived synthetic interleukins and interferons. After many decades of research, immunotherapy finally emerged as a fully functional
clinical area in the 1990s. Since then, the cancer therapeutics landscape has changed dramatically.
With the stream of product approvals in recent years, the global immunotherapy market has reached its current value. In 2015, the global cancer immunotherapy market hit $65 billion. The current immunotherapy market contains several blockbuster products reaching their end-of-market exclusivities; however, the market is mostly comprised of newly introduced and expensive therapies. In 2016, the market expanded by more than 10% over the previous year, reaching $73 billion. During the period of 2016 through 2021, the global cancer immunotherapy market is forecast to grow by a 5.7% compound annual growth rate (CAGR), reaching $96.5 billion in 2021.
The strongest growth is expected to occur in checkpoint-inhibitor drugs with a 19.4% CAGR during the forecast period. Immunomodulators are anticipated to show the second-highest growth rates among immunotherapy products, with an 8.4% CAGR during the same period. The combined sales from both segments are expected to make up for nearly one-third of the market, with a combined sales value of $28 billion in 2021. Checkpoint inhibitors are virtually comprised of monoclonal antibodies; however,
they are assessed separately due to their immense commercial and clinical significance. Sales from other therapeutic antibodies accrued to $28 billion in 2016, and this value is expected to remain relatively constant through 2021, due to several patent expiries, pressure from anticipated generic entries, and newly introduced classes of drugs expected by 2021.